anti-CEACAM5 antibody-drug conjugate BG-C477

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; carcinoembryonic antigen; CEA; CD66e) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-CEACAM5 ADC BG-C477, the monoclonal antibody moiety targets and binds to CEACAM5 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the CEACAM5-expressing cancer cells through an as of yet unknown mechanism of action. This inhibits the proliferation of CEACAM5-expressing tumor cells. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its expression is limited in normal. healthy, adult tissues, but is overexpressed in various cancers.